Technology Bundle ID
TAB-3689

An Antibody to Detect Phosphorylation (S1459) of the GRIN2A Gene to Study Epilepsy and Autism Spectrum Disorder

Linked ID
E-255-2020-0
Lead Inventors
Katherine Roche (NINDS)
Co-Inventors
John Badger (NINDS)
Marta Dias Da Mota Vieira (NINDS)
Research Products
Antibodies
Therapeutic Areas
Immunology
ICs
NINDS
This technology relates to the generation and use of an antibody that recognizes the S1459 phosphorylated site of the GRIN2A gene, which encodes the GluN2A subunit of the NMDA receptor. This gene is widely accepted as an epilepsy-causative gene and has been implicated in autism spectrum disorder (ASD). The S1459 phosphorylation site was selected based on an identified mutation in an epilepsy patient. This antibody can be used to specifically visualize the localization of the phosphorylated version of the GRIN2A protein product in the brain.
Commercial Applications
This GRIN2A antibody could potentially be used to visualize phosphorylation of this site in the brain.
Competitive Advantages
There are no other antibodies on the market that detect this specific phosphorylation site of the GRIN2A gene, GluN2A-S1459.

Request More Info

Licensing Contact: